Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon ? immunotherapy
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
A role for interleukin-6 (IL-6) in malignant mesothelioma has been suggested by the clinically presenting symptoms of mesothelioma patients, which include fever, weight loss and thrombocytosis. A murine model of malignant mesothelioma was therefore used to examine the potential role of IL-6 in this cancer type and whether the effect of interferon alpha (IFN alpha) therapy on mesothelioma might be mediated, in part, by regulating IL-6 levels and/or IL-6-induced pathobiology. A panel of human and murine mesothelioma cell lines was assayed for endogenous IL-6 production in a bioassay, and for IL-6-mRNA expression. Four out of 5 human and 5 out of 15 murine mesothelioma cell lines produced moderate to high levels of bioactive IL-6 in vitro. This result was corroborated by mRNA detection. One of the representative murine cell lines, AB22, was chosen for further in vivo studies in the murine mesothelioma model. In AB22-inoculated mice detectable serum IL-6 levels were found to precede macroscopically detectable tumour growth, clinical signs (cachexia, abdominal distension, diarrhoea) and changes in the peripheral lymphoid organs (cell depletion and functional depression). Treatment with anti-IL-6 antibody curtailed the clinical symptoms (P < 0.001), as did treatment with recombinant human (rhu) IFN alpha (P < 0.001). Neither anti-IL-6 antibody nor rhuIFN alpha had a direct growth-inhibitory effect on the AB22 mesothelioma cell line in vitro, however, in vivo rhuIFN alpha treatment of mice inoculated with AB22 cells attenuated both IL-6 mRNA expression in the tumours and serum IL-6 levels, ameliorated the depression of lymphocyte activities, and enhanced the number of tumour-infiltrating lymphocytes and macrophages. On the basis of these results it is suggested that IL-6 mediates some of these effects, directly or indirectly, and that a combination therapy of rhuIFN alpha and anti-IL-6 antibody may be an improved palliative treatment for patients with malignant mesothelioma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Van Snick, J. (1990) · Annual Review of Immunology · doi:10.1146/annurev.iy.08.040190.001345 · Cited by 1,890
Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
Strassmann, G., Fong, M., Kenney, J. S., & Jacob, C. O. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115767 · Cited by 658
Clinical toxicity of interferons in cancer patients: a review.
Quesada, J. R., Talpaz, M., Rios, A., Kurzrock, R., & Gutterman, J. U. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.234 · Cited by 596
MTT colorimetric assay for testing macrophage cytotoxic activity in vitro
Ferrari, M., Fornasiero, M. C., & Isetta, A. M. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90187-z · Cited by 565
Interleukin-6 is a potent thrombopoietic factor in vivo in mice
Ishibashi, T., Kimura, H., Shikama, Y., Uchida, T., Kariyone, S., Hirano, T., Kishimoto, T., Takatsuki, F., & Akiyama, Y. (1989) · Blood · doi:10.1182/blood.v74.4.1241.1241 · Cited by 432
Interferons and other regulatory cytokines
Demaeyer, E. M., & Maeyer‐Guignard, J. D. (1988) · Medical Entomology and Zoology · Cited by 419
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
Klein, B., Wijdenes, J., Zhang, X., Jourdan, M., Boiron, J., Brochier, J., Liautard, J., Merlin, M., Clement, C., & Morel-Fournier, B. (1991) · Blood · doi:10.1182/blood.v78.5.1198.1198 · Cited by 418
Diffuse Malignant Mesothelioma: Prospective Evaluation of 69 Patients
CHAHINIAN, A. P., PAJAK, T. F., HOLLAND, J. F., NORTON, L., AMBINDER, R. M., & MANDEL, E. M. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-6-746 · Cited by 354
Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis.
Motro, B., Itin, A., Sachs, L., & Keshet, E. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.8.3092 · Cited by 346
Interferons and other regulatory cytokines
Meager, A. (1989) · Journal of Immunological Methods · doi:10.1016/0022-1759(89)90301-3 · Cited by 304
Gélin, J., Moldawer, L. L., Lönnroth, C., Sherry, B. A., Chizzonite, R., & Lundholm, K. (1991) · PubMed · Cited by 251
Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen
McCormack, J. E., Callahan, J. E., Kappler, J., & Marrack, P. C. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.9.3785 · Cited by 234
Lu, C., & Kerbel, R. S. (1993) · The Journal of cell biology · doi:10.1083/jcb.120.5.1281 · Cited by 224
Through thick and thin: Wasting, obesity, and TNFα
Spiegelman, B. M., & Hotamisligil, G. S. (1993) · Cell · doi:10.1016/0092-8674(93)90243-j · Cited by 217
Establishment of a murine model of malignant mesothelioma
Davis, M. R., Manning, L. S., Whitaker, D., Garlepp, M. J., & Robinson, B. W. S. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520609 · Cited by 186
Self-citationLu, C., Vickers, M. F., & Kerbel, R. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9215 · Cited by 170
Kurzrock, R., Redman, J. R., Cabanillas, F., JONES, D. M., Rothberg, J. M., & Talpaz, M. (1993) · PubMed · Cited by 168
Pabst, R., & BINNS, R. M. (1989) · Immunological Reviews · doi:10.1111/j.1600-065x.1989.tb00014.x · Cited by 157
Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6
Oldenburg, H. S. A., Rogy, M. A., Lazarus, D. D., van Zee, K. J., Keeler, B. P., Chizzonite, R. A., Lowry, S. F., & Moldawer, L. L. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230824 · Cited by 155
Gene transfer and expression. A laboratory manual
(1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90278-q · Cited by 138
Stimulation of thrombopoiesis in mice by human recombinant interleukin 6.
Hill, R. J., Warren, M. K., & Levin, J. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114559 · Cited by 137
Schmitter, D., Lauber, B., Fagg, B., & Stahel, R. A. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510220 · Cited by 133 · cited 3×
“A role for IL-6 in mesothelioma-associated thrombocytosis has previously been suggested [ 30 ], whereas it has not yet been implicated in the, probably more important [23], symptoms such as fever and cachexia.”
BackgroundInfluentialKriegler, M. P. (1990) · Palgrave Macmillan UK eBooks · doi:10.1007/978-1-349-11891-5 · Cited by 121
The role of tumor necrosis factor (cachectin) in cachexia
Oliff, A. (1988) · Cell · doi:10.1016/0092-8674(88)90543-0 · Cited by 113
Strassmann, G., Jacob, C. O., Evans, R., Beall, D., & Fong, M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.11.3674 · Cited by 112
Manning, L. S., Whitaker, D., Murch, A. R., Garlepp, M. J., Davis, M. R., Musk, A. W., & Robinson, B. W. S. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910470219 · Cited by 100
Self-citationAnti‐human interleukin‐6 receptor antibody inhibits human myeloma growth in vivo
Suzuki, H., Yasukawa, K., Saito, T., Goitsuka, R., Hasegawa, A., Ohsugi, Y., Taga, T., & Kishimoto, T. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220806 · Cited by 93
Fitzpatrick, D. R., Bielefeldt-Ohmann, H., Himbeck, R. P., Jarnicki, A. G., Marzo, A. L., & Robinson, B. W. S. (1994) · Growth Factors · doi:10.3109/08977199409015049 · Cited by 90
Self-citationOhe, Y., Podack, E., Olsen, K., Miyahara, Y., Miura, K., Saito, H., Koishihara, Y., Ohsugi, Y., Ohira, T., Nishio, K., et al. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.174 · Cited by 79
Signaling for death of lymphoid cells
King, L. B., & Ashwell, J. D. (1993) · Current Opinion in Immunology · doi:10.1016/0952-7915(93)90055-w · Cited by 66
Utsumi, K., Takai, Y., Tada, T., Ohzeki, S., Fujiwara, H., & Hamaoka, T. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.1.397 · Cited by 65
Wang, R., MURPHY, K. M. M., Loh, D. Y., Weaver, C. T., & Russell, J. H. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.9.3832 · Cited by 60
Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study
Upham, J. W., Musk, A. W., van Hazel, G., Byrne, M., & Robinson, B. W. S. (1993) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1993.tb04727.x · Cited by 59
Self-citationBielefeldt‐Ohmann, H., Fitzpatrick, D. R., Marzo, A. L., Jarnicki, A., Himbeck, R. P., Davis, M. R., Manning, L. S., & Robinson, B. W. S. (1994) · Cancer Immunology Immunotherapy · doi:10.1007/bf01534421 · Cited by 57
Self-citationPotential for Interferon-α-Based Therapy in Mesothelioma: Assessment in a Murine Model
Bielefeldt‐Ohmann, H., FITZPATRICK, D. R., Marzo, A. L., Jarnicki, A., Musk, A. W., & Robinson, B. W. S. (1995) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1995.15.213 · Cited by 39
Self-citationResponsiveness of the interleukin (IL)-6-dependent cell line B9 to IL-11
Burger, R., & Gramatzki, M. (1993) · Journal of Immunological Methods · doi:10.1016/0022-1759(93)90266-a · Cited by 31
Bielefeldt‐Ohmann, H., Sabara, M. I. J., Lawman, M. J., GRIEBEL, P. J., & BABIUK, L. A. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.7.2201 · Cited by 30
Self-citationFITZPATRICK, D. R., WIE, J., Webb, D. H., BONFIGLIOLI, R., Gardner, I., Mathews, J. D., & Bielefeldt‐Ohmann, H. (1991) · Immunology and Cell Biology · doi:10.1038/icb.1991.49 · Cited by 19
Self-citationHasleton, P. S., & Hammar, S. P. (1996) · Current Diagnostic Pathology · doi:10.1016/s0968-6053(05)80013-4 · Cited by 14
Research works printed but not linked: 1
- Musk AW, Bowman RV, Christmas TI, Robinson BWS. Management of malignant mesothelioma. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D, editors. Malignant mesothelioma. New York: Hemisphere; 1992. pp. 292–302. [Google Scholar]
Cited by
Advances in Malignant Mesothelioma
Robinson, B. W. S., & Lake, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050152 · Cited by 889
Self-citationThe role of cytokines in cancer cachexia
Argilés, J. M. A., & López-Soriano, F. J. (1999) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199905)19:3<223::aid-med3>3.0.co;2-n · Cited by 258
Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma
Pinato, D. J., Mauri, F. A., Ramakrishnan, R., Wahab, L., Lloyd, T., & Sharma, R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823f45c1 · Cited by 150
The pivotal role of cytokines in muscle wasting during cancer
Argilés, J. M. A., Busquets, S., & López-Soriano, F. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.03.014 · Cited by 160
Nakano, T., Chahinian, A. P., Shinjyo, M., Tonomura, A., Miyake, M., Togawa, N., Ninomiya, K., & Higashino, K. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.150 · Cited by 122
Metadata
- Authors
- Bielefeldt-Ohmann, H., Marzo, A. L., Himbeck, R. P., Jarnicki, A. G., Robinson, B. W. S., & Fitzpatrick, D. R.
- Affiliations
- The University of Western Australia (AU)
- Venue
- Cancer Immunology Immunotherapy
- Published
- 1995-07
- Volume
- 40
- Issue
- 4
- Pages
- 241-250
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11037711
- OpenAlex
- W1980153171
- Cited by
- 52
- References
- 39
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2019: 1 · 2018: 3 · 2016: 2 · 2015: 4 · 2014: 2 · 2012: 3
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- UWA Profiles and Research Repository (University of Western Australia) (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- interleukin-6, malignant mesothelioma, interferon-alpha, anti-IL-6 antibody, IL-6 mRNA expression, cachexia, lymphocyte depletion, tumor-infiltrating lymphocytes, tumour-associated macrophages, palliative care
- MeSH terms
- Interleukin-6 Inhibitors, Animals, Base Sequence, Female, Humans, Immunotherapy, Interferon Type I, Mesothelioma, Mice, Inbred BALB C, Molecular Sequence Data, Recombinant Proteins, RNA, Messenger, Tumor Cells, Cultured, Interleukin-6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.